Featured Research

from universities, journals, and other organizations

Major gaps in hepatitis C care identified as new drugs, screening efforts emerge

Date:
July 2, 2014
Source:
Perelman School of Medicine at the University of Pennsylvania
Summary:
Significant gaps in hepatitis C care identified in a new meta-analysis will prove useful as the U.S. health care system continues to see an influx of patients with the disease because of improved screening efforts and new, promising drugs. In the largest study of its kind, the team examined data culled from 10 studies between 2003 and 2013 and found that less than 10 percent of people infected with hepatitis C in the United States -- 330,000 of nearly 3.5 million people -- were cured (achieved viral suppression) with antiviral hepatitis C treatment.

A new meta-analysis published online in PLOS ONE by infectious disease and epidemiology specialists from the Perelman School of Medicine at the University of Pennsylvania highlights significant gaps in hepatitis C care that will prove useful as the U.S. health care system continues to see an influx of patients with the disease because of improved screening efforts and new, promising drugs.

Related Articles


In the largest study of its kind, the team examined data culled from 10 studies between 2003 and 2013 and found that less than 10 percent of people infected with hepatitis C in the United States -- 330,000 of nearly 3.5 million people -- were cured (achieved viral suppression) with antiviral hepatitis C treatment. The researchers also found that only 50 percent of people were diagnosed and aware of their infection; 43 percent of those with the disease had access to outpatient care; and only 16 percent were prescribed treatment.

"This study puts forth a good baseline of hepatitis C care in the United States over the last 10 years -- which will be useful in monitoring the success and impact of new screening efforts and advances in antiviral therapy," said the study's first author, Baligh Yehia, MD, MPP, MSHP, an assistant professor of Medicine in Penn's division of Infectious Diseases. "There are many people who don't know that they have the infection, don't have access to hepatitis C care and medications, and who haven't been treated. With this data, we can see these gaps more clearly. This information will be useful for ensuring better access to hepatitis c care and treatment in the coming years."

In June, the Centers for Medicare and Medicaid Services began reimbursing for hepatitis C virus screenings for two target populations, including baby boomers (those born between 1945 through 1965) and those at high risk for the infection. Six months prior, the U.S. Food & Drug Administration (FDA) approved sofosbuvir, an oral medication shown to cure most cases of hepatitis C infection, with fewer side effects than the current treatment options. Other drugs -- which have shown success in clinical trials, some conducted at Penn Medicine -- are expected to gain FDA approval within the year.

"The new regimens will be game changers in the treatment of chronic hepatitis C," said senior author Vincent Lo Re III, MD, MSCE, assistant professor of Medicine and Epidemiology in the division of Infectious Diseases and department of Biostatistics and Epidemiology at Penn. "Given the high prevalence of this infection, particularly in baby boomers who didn't know they were infected, having new, highly-effective treatment options to eradicate the virus will be a tremendous benefit to patients that will ultimately help us to reduce liver-related complications and re-infection rates."

Such advances are expected to increase the number of patients treated for the disease. In the 1990s, HIV treatment turned a monumental corner with the advent of antiretroviral therapy. "It's a very similar situation that we can learn from," said Yehia. "With those advances, came challenges with access to and engagement in care. As hepatitis C therapy continues to advance, a focus on improving diagnosis, linkage to care, and insurance coverage will be more critical."

The team screened close to 10,000 articles before identifying 10 studies that address one or more steps in the cascade of care, ranging from diagnosis to viral suppression. Some of the data came from the National Health and Nutrition Examination Survey and the Chronic Hepatitis B and C Cohort study. The researchers addressed seven key steps along this cascade and estimated the following based off the data analyzed:

 Number of people with chronic hepatitis C infection -- 3.5 million

 Diagnosed and aware of their infection -- 1.7 million (50% of those with infection)

 Those with access to outpatient care -1.5 million (43% of those with infection)

 Hepatitis C RNA confirmed -- 950,000 (27% of those with infection)

 Disease staged by liver biopsy -- 580,000 (17% of those with infection)

 Prescribed treatment -- 550,000 (16% of those with infection)

 Achieved sustained virologic response -- 330,000 (9% of those with infection)

"The advent of new antiviral agents for hepatitis C will shorten treatment duration, likely increasing the number of people offered treatment, and improving cure rates, which are the final two steps of the hepatitis C treatment cascade," said Yehia. "However, educating providers and the general public about prevention, care, and treatment, ensuring access to providers skilled in the treatment of hepatitis C, and addressing the high cost of these agents will be critical to maximizing the benefits of these new therapies."


Story Source:

The above story is based on materials provided by Perelman School of Medicine at the University of Pennsylvania. Note: Materials may be edited for content and length.


Journal Reference:

  1. Baligh R. Yehia, Asher J. Schranz, Craig A. Umscheid, Vincent Lo Re. The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLoS ONE, 2014; 9 (7): e101554 DOI: 10.1371/journal.pone.0101554

Cite This Page:

Perelman School of Medicine at the University of Pennsylvania. "Major gaps in hepatitis C care identified as new drugs, screening efforts emerge." ScienceDaily. ScienceDaily, 2 July 2014. <www.sciencedaily.com/releases/2014/07/140702151355.htm>.
Perelman School of Medicine at the University of Pennsylvania. (2014, July 2). Major gaps in hepatitis C care identified as new drugs, screening efforts emerge. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2014/07/140702151355.htm
Perelman School of Medicine at the University of Pennsylvania. "Major gaps in hepatitis C care identified as new drugs, screening efforts emerge." ScienceDaily. www.sciencedaily.com/releases/2014/07/140702151355.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins